Somatic mutations of the BRAF gene are common in melanomas and nevi but the contribution of polymorphisms in this gene to melanoma or nevus susceptibility remains unclear. An Australian melanoma case-control sample was typed for 16 single nucleotide polymorphisms (SNP) within the BRAF gene, and five SNP in three neighboring genes. The sample comprised 755 melanoma cases from 740 families stratified by family history of melanoma and controls from 635 unselected twin families (2239 individuals). Ancestry of the cases and controls was recorded, and the twins had undergone skin examination to assess total body nevus count, degree of freckling, and pigmentation phenotype. Genotyping was carried out via primer extension followed by matrix-assisted laser desorption ionization-time of flight mass spectrometry. SNP in the BRAF gene were found to be weakly associated with melanoma status but not with development of nevi or freckles. The estimated proportion of attributable risk of melanoma due to variants in BRAF is 1.6%. This study shows that BRAF polymorphisms predispose to melanoma but the causal variant has yet to be determined. The burden of disease associated with this variant is greater than that associated with the major melanoma susceptibility locus CDKN2A, which has an estimated attributable risk of 0.2%.
The field of cancer genetics has produced notable successes applying genetic linkage analysis to identify genes that confer significant inherited susceptibility to particular cancers that show specific familial clustering. So far, these have been variants in genes of relatively large effect but which are rare in the general population, e.g., BRCA1 and BRCA2 in breast cancer and CDKN2A in melanoma, and thus do not account for a major contribution to overall population risks. Unlike these prominent cases it seems likely that most common cancers with an inherited component involve more genes, each conferring a fraction of the risk, and perhaps particular variants in multiple genes acting epistatically. Clearly, these are not readily amenable to discovery using the linkage approach and instead an association design may be more successful (Barrett et al, 2005) . Thus far, such association studies have had mixed results, arguably due to inadequate sample size and suboptimal study design (Risch, 2001) . Here, we present a large association study of the role in genetic predisposition to melanoma susceptibility of the BRAF gene, in a systematic and comprehensive haplotyping approach across the entire locus and adjacent genes.
The Ras/Raf/MAPK (mitogen-activated protein kinase) pathway is a critical molecular signaling cascade through which extracellular signals can be transmitted into the nucleus to regulate cell proliferation or differentiation through altered gene expression. Constitutive activation of this pathway is a frequent event in melanoma development (Cohen et al, 2002; Dong et al, 2003; Satyamoorthy et al, 2003) . Recently, BRAF gene somatic mutations have been shown to be associated with malignant melanoma , being present in 40%-88% of cutaneous melanomas (Brose et al, 2002; Davies et al, 2002; Dong et al, 2003; Gorden et al, 2003; Kumar et al, 2003; Pollock et al, 2003; Satyamoorthy et al, 2003) , whereas being essentially absent in control tissues. Mutations are also extremely common (74%-82%) in benign melanocytic nevi (Pollock et al, 2003; Yazdi et al, 2003) , an observation arguing for a critical role for B-Raf in initiating melanocytic neoplasia.
All somatic mutations documented to date in melanoma have been found in the kinase domain of B-Raf, encoded by exons 11 and 15 of the BRAF gene (Brose et al, 2002; Davies et al, 2002; Pollock et al, 2003; Satyamoorthy et al, 2003; Casula et al, 2004) (Fig 1) . The vast majority (over 90%) of these mutations affect codon 599 and result in a valine to glutamic acid substitution, see note added in proof which is thought to lead to constitutive activation of Ras/ Raf/MAPK signal transduction . Other less frequent BRAF coding somatic mutations in melanoma are G468A in exon 11 and L596V and Q608H in exon 15 Pollock et al, 2003; Casula et al, 2004) . In some melanomas without BRAF mutations, the MAPK pathway is constitutively activated through mutation of NRAS (van Elsas et al, 1996) . BRAF and NRAS mutations appear to have similar effects in melanoma development since their presence in any single tumor is mutually exclusive (Brose et al, 2002; Davies et al, 2002; Pollock et al, 2003; Satyamoorthy et al, 2003) . This situation is similar in lung (Brose et al, 2002; Davies et al, 2002; Naoki et al, 2002) , colon Rajagopalan et al, 2002; Yuen et al, 2002) , and thyroid cancers (Kimura et al, 2003) , where BRAF and RAS mutations are rarely found together.
To date, only one common germline BRAF coding variant has been reported, a synonymous G642G change (rs1042179 (NCBI, 2003) ). Although this particular variant was not tested, Meyer et al (2003b) recently described a case-control study (502 melanoma cases; 450 controls) assessing possible associations between intronic single nucleotide polymorphisms (SNP) in the BRAF gene and melanoma risk. Six of 12 SNP analyzed in this German case-control study were significantly (po0.05) more common in male cases than controls, but none of the SNP were significantly associated with melanoma risk in females, or when both sexes were combined. By contrast, Laud et al (2003) found no association between BRAF coding and intronic variants in a panel of 80 melanoma cases and 91 controls. More recently, a study of 569 Italian cases has revealed two types of germline variants (Casula et al, 2004) , which were previously unreported codon changes (M116R, Q608H; note this was misreported as G608H (Casula et al, 2005) ). The latter falls in exon 15 near the hotspot for somatic mutations that affect the kinase domain of the protein, whereas the former is of uncertain functional significance. One instance of the V599E substitution in germline DNA has subsequently been retracted (Casula et al, 2005) .
In this study, we sought to test the hypothesis that inherited polymorphisms of the BRAF gene predispose to the development of melanoma using a large case-control study. In addition, we attempted to detect association with nevus count and freckling phenotype in the general population.
Results
After data cleaning (Materials and Methods), there were 755 CMM (cutaneous malignant melanoma) cases with genotype information, and 46 unaffected genotyped relatives from the QFMP (Queensland Familial Melanoma Project). From the BTNS (Brisbane Twin Nevus Study), there were 2229 controls with genotype information after data cleaning and removal of one of each pair of the 159 monozygotic (MZ) twins. For the case-control analyses, there were 720 unrelated cases (mean age 52.9 y, 43.8% male) and 1170 unrelated controls (mean age 42.6 y, 44.8% male). We and others (Martin et al, 1997; Risch, 2001) have shown that unselected twin collections provide valid population controls since they represent a truly random proportion (1% of all births) of the general population. Previously, we reported no differences in mole counts between the twins and the general population from Queensland (Zhu et al, 1999 (Zhu et al, , 2004 . Over 95% of grandparents of both cases and controls are of Northern European ancestry, mainly from the British Isles. Mean Breslow thickness of melanomas in cases was 0.3 mm, and 21.4% were histologically graded as level I tumors.
All 16 SNP minor alleles were more common in cases than in controls, and the differences in frequency were statistically significant for 11 SNP (exceeding a critical threshold of 0.05, uncorrected for multiple testing; see Table I ) After correction for multiple testing, the best individual SNP permutation in p-value was 0.065. No SNP was significantly associated with melanoma when either males or females were considered separately, and indeed, there was no heterogeneity of risk between sexes. The highest genotypic relative risk was for the B11 SNP (rs1639679) in intron 11 (1.30, 95% CI ¼ 1.00-1.69, p ¼ 0.018). Adjusting for ancestry (proportion of grandparents born in the British Isles) did not alter the strength of this association.
The B5 (rs1267621) SNP minor allele frequency was highest in the high familial risk cases (Table I) , and a test for trend in family risk was significant (p ¼ 0.008). In the 10 cases (from eight high-risk families) carrying a mutation in CDKN2A, the major familial melanoma predisposition gene, none carried the rare allele (Table II) . (B11) rs1267606 (B4) rs1267601 (B5) rs1267609 (B6) rs1267649 (B7) rs1639675 (B8) rs1267636 (B9) rs1267646 (B10) rs1267639 (B13) rs1267638 (B14) rs1042179 (B15) CR1, Ras binding CR2 CR3, Kinase domain
Conserved regions:
Coding region The 16 BRAF SNP were in extremely tight linkage disequilibrium (LD), such that D 0 values for pairs of adjacent SNP ranged from 0.72 to 1 (Fig 2) . This degree of LD results in only three haplotypes defining 98% of chromosomes (Table III) . The strength of association of the common haplotypes combining the BRAF SNP was not greater than that evidenced by the individual SNP with melanoma (Table IV) . For example, SNP B5, or equivalently, the ''C'' haplotype, accounted for a proportion attributable risk estimated as 1.6% (95% CI ¼ 0.1%-3.1%). The histological level and Breslow thickness of tumors were not correlated with genotype, either for individual SNP or overall haplotype (Table IV) .
There was no association between any of the BRAF SNP and counts of total, macular, papular, or atypical nevi in the Australian controls (best p-value ¼ 0.16; see Table V) . Similarly, no association was seen with freckling (Table V) . Numbers of genotypes containing the ''C'' haplotype were not large, however. 
Discussion
The question of whether germline coding region mutations of the BRAF gene are responsible for predisposition in large multiple-case melanoma families has been investigated by several groups. The answer appears to be that such large impact mutations are not responsible for any significant proportion of familial or sporadic melanoma since no germline exon 15 BRAF mutations have been found after screening of 42 familial and two sporadic melanoma cases (Lang et al, 2003) ; 46 familial melanoma cases, 21 multiple melanoma cases, and 106 sporadic melanoma cases (Meyer et al, 2003a) ; 35 familial melanoma cases, 16 multiple melanoma cases, 18 uveal melanoma cases, and 11 probands from familes with melanoma nervous system tumors (Laud et al, 2003) , respectively. Most recently, however, a germline variant, Q608H, in exon 15 has been found (Casula et al, 2004; Casula et al, 2005) though its functional significance is unknown. Nevertheless, as 569 CMM cases were screened, the low incidence (0.18%) of these mutations cannot play a major role in melanoma susceptibility. In a similar vein, a recent study by Laud et al (2003) suggested that BRAF is also not a low-risk susceptibility gene for melanoma. This group screened the entire coding region of BRAF for germline mutations in melanoma-prone families and sporadic cases (n ¼ 80). They found 13 variants (four silent exonic and nine intronic), but none segregated in melanoma-prone families, and there were no significant differences in heterozygote frequencies between cases and controls for any of the 13 SNP. In stark contrast, the results of our study and that of Meyer et al (2003b) suggest that BRAF is indeed a low-risk susceptibility gene for melanoma. There are several plausible reasons for the discrepant results found between these studies. Laud et al analyzed a much smaller number of samples (n ¼ 80) compared to our study, in which 753 cases were utilized. The larger data set provides more power to detect SNP frequency differences, particularly if allele frequency differences are small SNP or Gene Position   ADCK2  BRAF  NDUFB2  Q9ULE3  MRPS33   B14  B15  B16  B3  B4  B5  B6  B7  B8  B10  B11  B12  B13  B9  B1  B2  M1  A1  Q1 Table I . yet significant. In addition, for each SNP, Laud et al calculated heterozygote frequencies and determined that there were no significant differences in frequencies between cases and controls for any SNP analyzed. In our study, in addition to genotype frequencies, allele frequencies were determined for cases and controls, and for three SNP located in BRAF, significant differences in frequencies between cases and controls were found, suggesting BRAF is a melanoma predisposition gene. A similar conclusion was reached by Meyer et al (2003b) , who found six SNP in BRAF were associated with melanoma risk in male cases (n ¼ 470), although not female cases (n ¼ 530), or males and females combined. The SNP B11 (rs1639679) and B5 (rs1267601) were associated with melanoma susceptibility in both the Australian and German case-control populations (see Table I ). The number of haplotypes spanning the 175 kb BRAF locus is surprisingly limited. In passing, the observed haplotypes exhibited what has been described as a ''yinyang'' phenomenon (Zhang et al, 2003) , in that the ''C'' haplotype differs at every site from the most common ''A'' haplotype. The causal variant(s) associated with melanoma risk is as yet unknown. As noted earlier, given the substantial sequencing of all exons and exon-intron junctions (Laud et al, 2003; Casula et al, 2004) it seems unlikely that there are any undiscovered coding changes common enough to account for our results. Newly described SNP in the promoter region are also unlikely to be relevant (Jackson et al, 2005) .
The hitherto best known melanoma genetic risk factor, CDKN2A, accounts for about 25% of familial melanoma cases (Pollock and Trent, 2000) , but less than 0.2% of the total melanoma burden (Aitken et al, 1999; Tsao et al, 2000) . Based on the observed genotype frequencies, we estimate that BRAF could account for a proportion attributable risk to develop melanoma of 1.6% in the Australian population. Our results suggest that, in addition to the high somatic mutation rate of BRAF in melanomas and nevi, germline polymorphisms in this gene also predispose to melanoma, although not to the development of nevi or freckles.
One would expect that if germline BRAF mutations are associated with increased risk of melanoma, then a similar strength of relationship with cutaneous nevus count would also be observed. We did not observe such a relationship with heterozygotes carrying the ''C'' haplotype, and there were only eight C/C homozygotes in the entire dataset, yielding little power, suggesting that there may be multiple independent pathways to the different phenotypes. We were not surprised by the lack of association between BRAF genotype and freckling, since an overlap in the mechanisms giving rise to freckling and to melanoma is less likely.
Materials and Methods
Participants We studied an Australian case-control sample made up of 755 melanoma cases from 740 families participating in the QFMP (Aitken et al, 1994; Aitken et al, 1996; Palmer et al, 2000) , and genotyped controls were 2239 individuals without melanoma from 635 twin families (476 DZ, 159 MZ) enrolled in the BTNS (Zhu et al, 1999 (Zhu et al, , 2004 . For purposes of a case-control analysis of melanoma, we used a subsample comprising 720 genotyped melanoma cases (one per family) and 1170 unrelated genotyped controls (parents of the twins individuals) used in calculations as indicated below. Ancestry of the cases and controls was recorded (grandparental country of birth and ethnicity), along with phenotypic risk factors such as hair and eye color, and tanning type.
Tumor thickness and level were recorded for the cases that included both in situ and invasive melanomas. A familial risk index was generated for the cases using a permutation-based procedure as described elsewhere (Aitken et al, 1994) . From this, three familial risk levels (''low'' (or ''sporadic''), ''intermediate,'' and ''high'') were classified that correspond approximately to having zero, one, or two or more first degree relatives affected with melanoma. These were used to further stratify the cases in terms of genetic risk. Only clinically verified cases among relatives were included in the analysis. No differences between genotypes are significant at the 5% level.
b Based on haplotypes given in Table III. Standard melanoma risk factors, including propensity to burn in the sun, pigmentation (skin color, hair color at 21 y, eye color, total freckling in summer, and density of melanocytic nevi) were obtained by mailed questionnaire with intensive telephone follow-up. Hair color was recorded as either black, dark brown, light brown, fair, or red/auburn and skin color was recorded as fair, medium, or olive/dark. A three-point scale was also used for eye color, including the categories blue/gray, green/hazel, and brown. Total freckling in summer was self-reported as either nil, 1-100, or 101 þ , and density of melanocytic nevi was estimated using a scale of nil, few, moderate, or many.
Skin color (on a three-point scale), hair color (on a five-point scale), and eye color (on a three-point scale) is therefore available for most of the cases and controls. Although nevus counts were only carried out in the adolescents, self-assessed nevus number on a four-point scale (''none,'' ''few,'' ''moderate,'' ''many'') is available for parents of the adolescents, as well as the melanoma cases.
Additional analyses of mole count has been performed using the BTNS twins and their siblings closest in age who have all undergone total body skin examination at age 12 y by a trained nurse who assessed nevus count, degree of freckling, and pigmentary phenotypes (Zhu et al, 1999) . Parents of the twins were genotyped, but only self-reported pigmentary characteristics are available, employing identical measures to those used to record these characteristics in the melanoma individuals. A four-point scale, however, was used to record freckle density, including no freckling, a few, some, and many freckles. No members of the BTNS had been diagnosed with melanoma at the time of this study. Approval to undertake this study was granted by the Human Research Ethics Committee of the Queensland Institute of Medical Research. All participants gave their signed informed consent. Australian National Health and Medical Research Council encompassing the Declaration of Helsinki Guidelines for human research were adhered to.
Genotyping Fifteen intronic/promoter and 1 exonic BRAF SNP were typed chosen on the basis of polymorphism in our collection and distribution across the gene (Table I, Fig 1) . In order to define flanking areas where linkage disequilibrium decayed around the 175 kb BRAF gene region we also typed five SNP in three flanking genes (MRPS33, ADCK2, and Q9ULE3), which extended an additional 232 and 77 kb on either side and spanning 484 kb in total. SNP identity and type is given in Table I ; full sequence and other linked information may be found in the public databases by using the unique ''rs'' accession number (NCBI, 2003) . Genotyping was performed via a primer extension reaction and matrix-assisted laser desorption ionization-time of flight mass spectrometry (Mass-ARRAY, Sequenom, San Diego, California) as previously described (Bansal et al, 2002; James et al, 2004) . All SNP had dropout rates of o0.5%. Data cleaning involved examining Mendelian inconsistencies, departures from Hardy-Weinberg Equilibrium, and discordances between MZ pairs. After examination, where the Mendelian errors were encountered the entire family was dropped from analysis. Error rates due to genotyping technical causes, estimated by replicate typing and use of 159 MZ twin pairs, were found to be 0.11%-0.2%, respectively.
Statistical analysis The use of the BTNS families as controls greatly increases our ability to detect genotyping problems, but makes the analysis more complex. We have extracted unrelated cases and controls, and performed multiple logistic regression analysis versus individual SNP, and Fisher-Irwin Exact tests comparing genotype counts in cases and controls. Correction for multiple testing versus individual SNP was done by repeatedly permuting cases and controls, retaining the best text statistic out of 21 tests from each of 100,000 replicates. Given that this is a replication of a previously reported association it is not necessary to apply a genome-wide level correction. Haplotypic association analysis was performed using the haplo.stat package (Lake et al, 2002) running in R (RDCG, 2004) , cross-checking with the COCA-PHASE program (Lang et al, 2003) . These programs use an EM algorithm to enumerate all legal haplotypes that could give rise to an observed genotype and estimate the posterior probabilities for these haplotypes for each individual. Association is then assessed via binomial (or ordinal logistic or linear) regression using the haplotype probabilities as weights. This approach allows covariates to be easily included. Proportion attributable risk was calculated using the control genotype frequencies and the estimated genotypic odds ratios (PAR ¼ 1À1/(p 2 g 2 þ 2p(1Àp)g 1 þ (1Àp) 2 ), where p is the risk allele frequency, and g 2 and g 1 the genotypic relative risks for risk allele homozygotes and heterozygotes).
Note added in proof NCBI-Genbank has renumbered Braf codons such that the previous 599 is now 600.
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